Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials

By afschroeder • October 22, 2025

Mayo T, Silverberg JI, Armstrong A, Guttman-Yassky E, Blauvelt A, Esdaile B, Kabashima K, Gooderham M, Kircik L, Schneider S, Bennike N, von Eyben R, Martel BC, Røpke MA, Katoh N, Alexis AF. Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials. Am J Clin Dermatol. 2025 Oct 21. doi: 10.1007/s40257-025-00985-1. Epub ahead of print. PMID: 41118053.

Tags: Dermatology, Publications

Temporal CRAC channel blockade modulates the MYC-MXD axis to attenuate autoimmune inflammation

Wu B, Hasiakos S, Cokus S, Do M, Kaplan E, Pellegrini M, Sun Z, Kim RH, Srikanth S, Gwack Y. Temporal CRAC channel blockade modulates[...]

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Armstrong A, Merola JF, Chughtai R, Fotiou K, Ngantcha M, Sabatino S, Megna M, Man X, Honma M, Carrascosa JM, Pinter A. Early and Maintained[...]

Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline

Smart K, Armstrong AW, Adler BL. Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline. Dermatitis. 2026 Sep[...]